Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 17/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.39 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21069325 | 0.88 | PDK4 (0.50) | CRBNDDB1 | |
| SCHEMBL21997875 | 0.85 | CRBN (0.45) | CRBNDDB1IKZF1IKZF2 | |
| SCHEMBL29347198 | 0.84 | PDK4 (0.49) | CRBNDDB1 | |
| SCHEMBL29077504 | 0.82 | CRBN (0.49) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24607909 | 0.82 | CRBN (0.48) | CRBNDDB1 | |
| SCHEMBL29751470 | 0.82 | CRBN (0.48) | CRBNDDB1 | |
| SCHEMBL26447957 | 0.81 | DDB1 (0.58) | CRBNDDB1IKZF1ALDH1A1CHRM2 | |
| SCHEMBL27179003 | 0.81 | CRBN (0.53) | CRBNDDB1IKZF1IKZF2ALDH1A1 | |
| SCHEMBL29502436 | 0.80 | CRBN (0.51) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL22836025 | 0.80 | CRBN (0.50) | CRBNDDB1IKZF1ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024245169-A1 | PROTAC COMPOUND TARGETING ESTROGEN RECEPTOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 北京盛诺基医药科技股份有限公司 | 2024-12-05 | — | — | WO | disclosed |
| CN-119013277-A | TYK2 degrading agent and application thereof | 凯麦拉医疗公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | CRBN 111/4885DDB1 2403/4885IKZF1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.